5326492026-04-012026-06-305326492026-04-012026-06-30in-capmkt:OtherExpenses1Member5326492026-04-012026-06-30AuditorDomain1iso4217:INRiso4217:INRxbrli:shares532649NECLIFENOTLISTEDINE023H01027Nectar Lifesciences LimitedMain BoardEquity2026-04-012027-03-312026-08-142026-08-10INRLakhsQuarterlyFirst quarterSingle segmentPharmaceutical Business Segment2026-08-1419:30:002026-08-1420:35:00Declaration of unmodified opinionfalsefalseThere is no default by the Company on its loans. The Company has not issued any debt securities.2026-04-012026-06-30UnauditedStandalone14500062802000629470000275000-1380001032800015690001106000266356000279496000-2165490000-2165490000-81987000-819870000-1345620004935000172500032100000-1313520000-1313520001942610001-0.69-0.690.020.02-0.67-0.67Notes <br /> <br /> 1. The above financial results were reviewed by Audit Committee on August 14, 2026, and approved by the Board in its meeting held on August 14, 2026. The statutory auditors of the Company have conducted a “Limited Review” of the above standalone and consolidated unaudited financial results for the quarter ended on June 30, 2026. <br /> <br /> 2. The Company is exclusively in the pharmaceutical business segment. <br /> <br /> 3. Previous period’s figures have been regrouped and reclassified wherever necessary to make them comparable with current period. <br /> <br /> 4. The figures of the last quarter for the previous financial year i.e. March 31, 2026, are the balancing figures between the audited figure in respect of the full previous financial year ended March 31, 2026, and the unaudited published year to date figures up to the third quarter ended December 31, 2025, which was subject to limited review and not audit. <br /> <br /> 5. The Company has two wholly owned subsidiaries with the following details: - <br /> <br /> a) Neclife PT, Unipessoal LDA, remained inoperative during the period. <br /> <br /> b) Avensis Exports Private Limited (“AEPL”). <br /> <br /> 6. The Company is "Not a Large Corporate" as per the framework provided in the SEBI Circular dated October 19, 2023, on Fund raising by issuance of debt securities by Large Entities. <br /> <br /> 7. Going Concern <br /> <br /> During the previous financial year, the Company had sold a substantial part of its existing business operations by way of slump sale and incurred losses. The transaction had resulted in significant liquidity, and the Company, after discharging all its debts, continues to possess adequate cash and liquid resources to meet its obligations, if any. Further, the Company had amended its object clause to undertake activities in the real estate sector and is currently evaluating the various projects under the revised business framework. In furtherance of this objective, the Company had also acquired AEPL as its wholly owned subsidiary. Considering the Company’s solvent financial position and availability of funds, the Board believes that the Company will continue to operate as a going concern for the foreseeable future. Accordingly, the financial results have been prepared on a going concern basis. <br /> <br /> 8. Material Transactions <br /> <br /> A. Assets Classified as Held for Sale <br /> <br /> a. Capsule Business (EHGC) <br /> <br /> The Company had entered into a Business Transfer Agreement (“Capsule BTA”) dated December 20, 2025, with Capnest Health Care Private Limited (“Capnest”) for the slump sale of its Empty Hard Gelatin Capsule business located at Village Bhatoli Kalan, Pargana Dharmpur, Tehsil Baddi, District Solan, Himachal Pradesh (“Capsule Business”), on a going concern basis, for a consideration of Rs.1,990.00 lakhs, including transfer of related receivables and payables/creditors, subject to working capital adjustments specified in the Capsule BTA and approval under Section 118 of the Himachal Pradesh Tenancy and Land Reforms Act, 1972. The transaction shall be completed in accordance with the terms set out in the Capsule BTA. <br /> <br /> b. Other Assets <br /> <br /> The Company is also evaluating the monetization of the following assets with the objective of optimizing non-core assets and further strengthening its liquidity position: <br /> <br /> (i) Jammu Unit: Fixed assets pertaining to the Company’s Jammu unit, which has remained inoperative. The same has been disposed of in the subsequent quarter, and the impact thereof will be disclosed accordingly. <br /> <br /> (ii) Land near Garhshankar, Punjab: Vacant land situated near Garhshankar, Punjab. A portion of the said land has already been sold in the current quarter, and the balance is expected to be sold by the end of this financial year. <br /> <br /> Accordingly, the results relating to the above disposed businesses/assets have been disclosed as discontinued operations in accordance with Ind AS 105. <br /> <br /> Further, in the audited standalone financial results, the net result of “Capsule Business” has been disclosed separately as discontinued operation as required by Indian Accounting Standard (Ind AS) 105 – Asset Held for Sale and Discontinued Operations and Schedule Ill to the Companies Act, 2013. Consequently, the Company's Statement of Profit and Loss for the period ended June 30, 2026, pertains to its continuing operations only and for that purpose the results for the other reporting periods i.e., March 31, 2026, and June 30, 2025, have been restated accordingly. <br /> <br /> Standalone Operations relating to the “Capsule Business” in respect of total income, total expenses and tax are being disclosed separately as Discontinued operations as part of the results below: <br /> Rs. in lakhs <br /> S. No. Particulars Quarter Ended Year Ended <br /> 30-Jun-26 31-Mar-26 30-Jun-25 31-Mar-26 <br /> Restated <br /> Unaudited Audited Unaudited Audited <br /> 1 Revenue from operations 574.14 571.35 28,066.50 40,138.43 <br /> 2 Other income 5.45 0.18 4.68 1,221.82 <br /> 3 Total expenses 530.24 7,892.12 37,760.15 95,125.77 <br /> 4 Profit before tax 49.35 (7,320.59) (9,688.97) (53,765.51) <br /> 5 Exceptional item <br /> (Gain on slump sale) - - - 16,337.32 <br /> 6 Tax expenses 17.25 (4,249.39) (3,357.08) (13,873.82) <br /> 7 Net profit after tax 32.10 (3,071.20) (6,331.89) (23,554.37) <br /> <br /> 9. Pursuant to the approvals granted by the Board, the Company deployed certain surplus funds in mutual fund, ETF and equity instruments during the year. Subsequently, volatility in the financial markets arising from prevailing market conditions and geopolitical developments adversely impacted the value of such investments, resulting in a loss of Rs.2,513.29 lakhs. The resultant impact has been recognized in the Statement of Profit and Loss in accordance with Ind AS 109 – Financial Instruments. <br /> <br /> <br /> Other Expenses266356000UnauditedtrueDeepak Jindal & Co.true2027-05-31